Dosage and administration of Fexprazan injection composition
An injectable Fexprazan composition addresses the need for faster treatment by maintaining gastric pH, effectively reducing gastrointestinal bleeding and ulceration, with doses optimized for intravenous administration.
Patent Information
- Application Number
- JP2024533293
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-15
- Filing Date
- 2022-12-15
- Publication Date
- 2024-12-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
There is a need for an injectable form of Fexprazan, a substance with anti-ulcer and Helicobacter pylori eradication activity, to provide faster and more effective treatment for gastrointestinal tract diseases, as oral preparations are inadequate for certain patients.
Development of an injectable composition of Fexprazan, specifically formulated to provide doses ranging from 10 mg to 90 mg per day, administered intravenously, to maintain gastric pH at 6 or higher for 50% of the day, and formulated with pharmaceutically acceptable salts and carriers.
The injectable Fexprazan composition effectively maintains gastric pH, reducing bleeding and ulceration, with therapeutic effects comparable to oral administration, and demonstrates safety and efficacy in clinical trials.
Smart Images

Figure 2024545449000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to an appropriate dosage regimen for a fexprazan injectable composition. [Background technology]
[0002] The annual incidence of hospitalizations for acute upper gastrointestinal bleeding in the United States is 160 per 100,000 population, translating to more than 400,000 cases per year. The vast majority of upper gastrointestinal bleeding cases (80-90%) are non-variceal bleeding, the most common of which is gastric or duodenal peptic ulcers. The most common cause of upper gastrointestinal bleeding is peptic ulcers, accounting for approximately 50% of cases, and Helicobacter peptic ulcers are the most common cause of upper gastrointestinal bleeding. Peptic ulcers are defined as those that occur when aggressive factors such as gastric acid and pepsin prevail over defensive factors such as mucus, resulting in a defect in the gastrointestinal mucosa due to aggressive factors. Common causes of peptic ulcers include Helicobacter infection, use of nonsteroidal anti-inflammatory drugs, and physical stress. In some cases of iatrogenic ulcers, ulcers may occur due to endoscopic mucosal resection or endoscopic submucosal dissection.
[0003] Treatment methods for ulcerative bleeding include endoscopic treatment, drug treatment, and surgical treatment. Drug treatment is mainly performed by using injections to quickly and strongly suppress gastric acid secretion. Gastric acid damages the blood clotting process, promotes platelet aggregation and destruction, and favors fibrinolysis. Therefore, suppressing gastric acid secretion, increasing intragastric acidity, and maintaining the increased pH at night promotes the stabilization of the blood clotting process and reduces the tendency for rebleeding. However, even high-dose injections of PPIs (proton-pump inhibitors) act irreversibly on the intragastric proton pump, so the proton pumps in newly generated parietal cells cannot be continuously suppressed, and early drug resistance makes it difficult to obtain meaningful treatment results.
[0004] P-CABs (potassium-competitive acid blockers) overcome the shortcomings of existing gastric acid secretion inhibitors, PPIs, by reversibly binding to the proton pump to inhibit gastric acid secretion. They are highly stable against gastric acid, are not pro-drugs, and act directly on the proton pump, with advantages such as rapid onset of action, strong efficacy, long half-life, and the ability to be administered without being affected by food. Based on these advantages, they are carving out a new market for gastric acid secretion inhibitors. Substances such as vonoprazan and tegoprazan have been commercialized and are mainly used to treat gastric acid-related diseases, especially gastroesophageal reflux disease (GERD).
[0005] Despite this, an injectable formulation for P-CAB preparations has not yet been developed, and there have been difficulties in administering the drug to patients who require a faster effect than oral agents can provide or who are unable to take oral agents.
[0006] "1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine", named fexprazan, is a substance described in Korean Patent Registration No. 10-1613245, and is known to be useful for preventing and treating gastrointestinal ulcers, gastritis, reflux esophagitis, or gastrointestinal damage caused by Helicobacter pylori, due to its excellent anti-ulcer activity (i.e., proton pump inhibitory activity, etc.), Helicobacter pylori eradication activity, and GPCR inhibitory activity.
[0007] Fexprazan is known to be effective in treating diseases associated with gastric acid secretion, specifically, gastroesophageal reflux disease (GERD), and more specifically, erosive esophagitis (EE), when orally administered at a dose of 40 mg once daily.
[0008] Therefore, the present inventors developed an injectable composition for fexprazan and, through intensive research into the composition, confirmed appropriate therapeutic dosages and administration methods of the fexprazan injectable composition for each indication, thereby completing the present invention. Summary of the Invention [Problem to be solved by the invention]
[0009] The present invention provides appropriate dosage regimens for fexprazan injectable compositions according to each indication. [Means for solving the problem]
[0010] In order to solve the above problems, the present invention provides an injectable composition for preventing or treating gastrointestinal diseases, comprising a compound represented by the following chemical formula 1 or a pharma- ceutical acceptable salt thereof, administered at a dose 0.4-0.6 times the dose at which a therapeutic effect has been confirmed for oral administration: <Chemical formula 1> JPEG2024545449000002.jpg4967
[0011] The chemical name of the compound represented by Chemical Formula 1 is 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine, which is a substance described in Korean Patent Registration No. 10-1613245.
[0012] The compound is an active ingredient that exhibits the pharmacological effects of the injectable composition according to the present invention, and has excellent anti-ulcer activity (i.e., proton pump inhibitory activity, etc.), Helicobacter pylori eradication activity, and GPCR inhibitory activity, and is therefore useful for preventing or treating gastrointestinal ulcers, gastritis, reflux esophagitis, or gastrointestinal damage caused by Helicobacter pylori.
[0013] In addition, the compounds as well as pharma- ceutically acceptable salts of the compounds can be used in the present invention. As salts, salts commonly used in the art, such as acid addition salts formed with pharma- ceutically acceptable free acids, can be used without limitation. The term "pharma-ceutically acceptable salt" as used herein means any organic or inorganic addition salt of the compound that is relatively non-toxic and harmless to patients at a concentration having an effective effect, and the side effects caused by the salt do not reduce the beneficial efficacy of the compound represented by Chemical Formula 1.
[0014] A pharma- ceutically acceptable salt can be obtained by a conventional method using an inorganic or organic acid. For example, the compound represented by the formula 1 can be dissolved in a water-miscible organic solvent, such as acetone, methanol, ethanol, or acetonitrile, and an organic or inorganic acid can be added to the solution, and the precipitated crystals can be filtered and dried to obtain a pharma-ceutically acceptable salt. Alternatively, the solvent or excess acid in the reaction mixture to which the acid is added can be reduced in pressure, and the residue can be dried, or another organic solvent can be added to the solution, and the precipitated salt can be filtered to obtain a salt. In this case, preferred salts include salts derived from hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, glycolic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, mandelic acid, tartaric acid, citric acid, ascorbic acid, palmitic acid, maleic acid, hydroxymaleic acid, benzoic acid, hydroxybenzoic acid, phenylacetic acid, cinnamic acid, salicylic acid, methanesulfonic acid, benzenesulfonic acid, or toluenesulfonic acid.
[0015] Meanwhile, the injectable composition of the present invention can be formulated according to standard pharmaceutical practice, and these formulations can contain, in addition to the active ingredient, additives such as pharma- ceutically acceptable carriers, adjuvants, or diluents. In particular, suitable carriers for preparing an injectable composition can be used, such as physiological saline, polyethylene glycol, ethanol, vegetable oil, and isopropyl myristate, and diluents can be, but are not limited to, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, and / or glycine. In addition, the injectable composition can be dissolved in oil, propylene glycol, or other solvents that are commonly used in the preparation of injectable compositions.
[0016] In addition, the term "prevention" as used herein means any action of suppressing or delaying the onset, spread, and recurrence of the disease by administering the injectable composition of the present invention, and "treatment" as used herein means any action of improving or favorably modifying the symptoms of the disease by administering the injectable composition of the present invention.
[0017] Preferably, an injection composition containing the compound represented by Chemical Formula 1 or a pharma- ceutically acceptable salt thereof is administered once a day at a dose of 10 mg to 30 mg for the prevention or treatment of gastrointestinal diseases. In this case, the mass of 10 mg to 30 mg refers to the amount of the compound represented by Chemical Formula 1 administered, and in the case of using a pharma- ceutically acceptable salt of the compound represented by Chemical Formula 1, it refers to the amount excluding the salt component. In addition, the administration is preferably intravenous.
[0018] The gastrointestinal disease is a disease related to gastric acid secretion. The gastric acid secretion-related disease is a common name for digestive system diseases related to gastric acid, such as gastric ulcer, duodenal ulcer, erosive reflux esophagitis, and non-erosive gastroesophageal reflux disease, and the disease can be cured or its symptoms alleviated by suppressing or removing the gastric acid secretion that is the cause of the disease. Gastroesophageal reflux disease (GERD) is a condition in which unpleasant symptoms and complications are induced by gastric contents refluxed into the esophagus. It is classified into erosive esophagitis (EE) and non-erosive reflux disease (NERD) depending on the presence or absence of morphological changes such as ulcers and erosions in the esophagus. Erosive esophagitis is defined as damage that can be identified with the naked eye in the distal esophageal mucosa endoscopically, and non-erosive esophagitis is defined as damage to the esophageal mucosa that is not endoscopically damaged, even if typical reflux symptoms are present.
[0019] In the present invention, it has been confirmed that when a condition of pH 4 or more is maintained for 40% or more of the day, there is a therapeutic effect on diseases related to gastric acid secretion, specifically, gastroesophageal reflux disease, and more specifically, erosive esophagitis. When the compound represented by the above formula 1 or a pharma- ceutical acceptable salt is orally administered once a day at 40 mg, it has a therapeutic effect on diseases related to gastric acid secretion, specifically, gastroesophageal reflux disease, and more specifically, erosive esophagitis, and in the present invention, it has been confirmed that when the same compound is administered intravenously at 10 mg to 30 mg once a day, it has the same effect as oral administration.
[0020] Preferably, the injectable composition containing the compound represented by Chemical Formula 1 or a pharma- ceutically acceptable salt thereof is administered at 20 mg once a day for the prevention or treatment of gastrointestinal diseases.
[0021] The present invention also provides an injection composition for treating bleeding, which is administered once a day at 70 mg to 90 mg or twice a day at 30 mg to 50 mg of the compound represented by Chemical Formula 1 or a pharma- ceutically acceptable salt thereof. In this case, the masses of 70 mg to 90 mg and 30 mg to 50 mg respectively refer to the amount of the compound represented by Chemical Formula 1 administered, and when a pharma- ceutically acceptable salt of the compound represented by Chemical Formula 1 is used, the amount does not include the salt component.
[0022] Gastric acid makes the blood clotting process difficult and dissolves aggregated platelets and fibrin. Therefore, in order to treat bleeding, gastric acid secretion must be regulated to maintain a high intragastric pH, and the higher the intragastric pH and the longer it is maintained, the better the therapeutic effect against bleeding. However, it is generally known that when the intragastric acidity pH is 6 or more, the blood clotting process is stabilized and rebleeding is reduced, and a treatment effect is achieved when a pH of 6 or more is maintained for 50% or more of the day. In the present invention, it has been confirmed that such conditions are satisfied when an injection composition containing the compound represented by Formula 1 or a pharma- ceutical acceptable salt thereof is administered once a day at 70 mg to 90 mg, or twice a day at 30 mg to 50 mg. In addition, the bleeding is bleeding due to peptic ulcer or bleeding due to iatrogenic ulcer after endoscopic surgery.
[0023] Preferably, the injectable composition containing the compound represented by Formula 1 or a pharma- ceutically acceptable salt thereof is administered at 80 mg once a day or 40 mg twice a day for the treatment of bleeding.
[0024] The present invention also provides an injectable composition for preventing bleeding, which comprises administering the compound represented by Chemical Formula 1 or a pharma- ceutical acceptable salt thereof at a rate of 30-50 mg, followed by a sustained administration rate of 1 mg / h-10 mg / h for 24 hours or more. In this case, the mass of 30-50 mg and the rate of 1 mg / h-10 mg / h refer to the amount of the compound represented by Chemical Formula 1 administered, and in the case of using a pharma- ceutical acceptable salt of the compound represented by Chemical Formula 1, the amount refers to the amount excluding the salt component. In addition, the sustained administration method generally includes a method of diluting the fexprazan injection composition in physiological saline (bag), connecting it to an infusion set, and then adjusting the administration rate and administration time.
[0025] In order to prevent bleeding, intragastric pH must be maintained at a certain level or higher, and generally, a preventive effect is achieved when a condition of pH 6 or higher is maintained for 50% or more of the day. In the present invention, it has been confirmed that such a condition is satisfied when an injection composition containing the compound represented by Chemical Formula 1 or a pharma- ceutical acceptable salt thereof is administered at 30-50 mg, followed by continuous administration at 1 mg / h-10 mg / h for 24 hours or more.
[0026] Preferably, the injectable composition containing the compound represented by Formula 1 or a pharma- ceutical acceptable salt thereof is administered at a dose of 40 mg, followed by a sustained administration of 1-10 mg / h for 48 hours or more to prevent bleeding. Effect of the Invention
[0027] As described above, the present invention provides an appropriate dosage regimen of a fexprazan injection composition according to each indication, thereby enabling optimal preventive or therapeutic effects to be obtained. [Brief description of the drawings]
[0028] [Figure 1] 1 is a diagram illustrating the clinical trial method of Experimental Example 4. [Diagram 2]The plasma concentrations of fexprazan after single intravenous administration of 10 mg, 20 mg, 40 mg, and 80 mg are shown in Figure 2A on a linear scale, and in Figure 2B on a semi-log scale. [Diagram 3] The relationship between the dose and plasma concentration of fexprazan injection when administered intravenously is shown. Power model graphs show the logarithm of plasma Cmax value (Fig. 3A), the logarithm of plasma AUClast value (Fig. 3B), and the logarithm of plasma AUCinf value (Fig. 3C) against the logarithm of the administered dose of fexprazan in each dose group. [Figure 4] The figures show the dose-normalized results of Cmax, AUClast, and AUCinf values following single administration of 10 mg, 20 mg, 40 mg, and 80 mg of fexprazan injection. Figure 4A shows the Cmax, Figure 4B shows the AUClast, and Figure 4C shows the AUCinf parameter values, each normalized by the administered dose, for fexprazan. [Diagram 5] The graph shows the change in gastrointestinal acidity over time following single administration of 10 mg, 20 mg, 40 mg, and 80 mg of fexprazan injection. [Figure 6] 1 is a diagram illustrating the clinical trial method of Experimental Example 5. [Figure 7] This shows the change in gastrointestinal acidity over time following oral and intravenous administration of 40 mg of fexprazan. [Figure 8] 1 shows a test outline for dose groups 1 and 3 in Experimental Example 6 of the present invention. [Figure 9] 1 shows a test outline for dosage group 2 in Experimental Example 6 of the present invention. [Figure 10] 1 shows the results of testing gastrointestinal acidity (pH) for Dosage Group 1 in Experimental Example 6 of the present invention. [Figure 11] 1 shows the results of testing gastrointestinal acidity (pH) for Dosage Group 2 in Experimental Example 6 of the present invention. [Figure 12]1 shows the results of testing gastrointestinal acidity (pH) for Dosage Group 3 in Experimental Example 6 of the present invention. [Figure 13] 1 shows the time during which the pH in the gastrointestinal tract is maintained at 4 or higher in Experimental Example 6 of the present invention. [Figure 14] 1 shows the time during which the pH in the gastrointestinal tract is maintained at 6 or higher in Experimental Example 6 of the present invention. [Figure 16] 1 shows a test outline of Experimental Example 7 of the present invention. [Figure 16] 1 shows the change in acidity in the gastrointestinal tract over time in Experimental Example 7 of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0029] Hereinafter, preferred examples will be presented to aid in understanding the present invention. However, the following examples are merely illustrative of the present invention, and the scope of the present invention is not limited to the following examples.
[0030] Manufacturing Example JPEG2024545449000003.jpg5680
[0031] The compound represented by formula 1 of the present invention was prepared in the same manner as in Example 8 of Korean Patent Application No. 10-2016-0013588.
[0032] Molecular weight 446.87 1H-NMR (500 MHz, MeOD): 7.69(s, 1H), 7.58-7.53(m, 1H), 7.45(t, 1H), 7.30(d, 1H), 7.20-7.15(m, 2H), 7.02-6.94(m, 2H), 4.07(d, 2H), 3.46(s, 3H), 2.71(s, 3H)
[0033] Experimental Example 1: Confirmation of the effectiveness of Fexprazan injection in treating bleeding / ulcers To evaluate the efficacy of fexprazan against gastric bleeding ulcer, an indomethacin-induced gastric bleeding ulcer model was used in male rats.
[0034] Specifically, the above-prepared 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine (hereinafter referred to as "fexprazan") hydrochloride was dissolved in a solution containing 30 wt% polyethylene glycol (Polyethylene Glycol 400) polymer in physiological saline, and the concentration was adjusted so that 0, 0.1, 0.5, 1, and 2 mg / kg of fexprazan could be administered to each test animal in a liquid volume of 1 mL / kg, and then each was administered once via the tail vein to the test animals. In addition, esomeprazole magnesium trihydrate, which is a positive control group, was administered once via the tail vein to the test animals in an amount of 1 mg / kg of esomeprazole by weight. After 30 minutes, indomethacin 80 mg / kg was orally administered once to each test animal to induce gastric bleeding and ulcer. Five hours after indomethacin administration, a dissection was performed and the stomach was removed. The gastric ulcer index (%) was measured using an image program (Leica Application Suite V4), and the gastric hemorrhage and erosion state was evaluated by histopathological examination. The results are shown in Table 1 below.
[0035] [Table 1]
[0036] As shown in Table 1, the fexprazan group showed a statistically significant reduction in gastric ulcer index and levels of congestion and erosion compared to the vehicle group, demonstrating gastroprotective and anti-bleeding effects, and the minimum effective dose was 0.5 mg / kg.
[0037] Experimental Example 2: Pharmacokinetics of Fexprazan Injection Methylcellulose was dissolved in saline to prepare a solution containing 0.5 wt% methylcellulose, and the prepared fexprazan hydrochloride was added thereto to prepare a composition with a fexprazan concentration of 1 mg / mL. The prepared composition was orally administered to male rats at a dose of 2 mg / kg depending on the individual's body weight in a volume of 2 mL / kg, and blood was collected by orbital blood sampling at 0.25, 0.5, 1, 2, 4, 6, 8, and 24 hours after administration, and plasma was collected by centrifugation at 10,000 rpm for 5 minutes, and analyzed by HPLC-MS / MS to calculate pharmacokinetic parameters.
[0038] Methylcellulose was dissolved in saline to prepare a solution containing 0.5 wt% methylcellulose, and the prepared fexprazan hydrochloride was added thereto to prepare a composition with a fexprazan concentration of 1 mg / mL. The composition was administered to male rats via the tail vein at a dose of 1 mg / kg depending on the individual's body weight in a volume of 1 mL / kg, and blood samples were collected 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, and 24 hours after oral administration and analyzed. The analytical results are shown in Table 2 below.
[0039] [Table 2]
[0040] Experimental Example 3: Toxicity test results of Fexprazan injection The fexprazan hydrochloride prepared above was dissolved in a solution containing 30 wt% polyethylene glycol (Polyethylene Glycol 400) polymer in physiological saline, and the concentration was calculated so that the solution volume could be administered at 5mL / kg for rats and 2mL / kg for beagles based on the weight of fexprazan, and each composition was prepared and administered intravenously to rats and beagles at 0, 2.5, 5, and 10mg / kg / day once a day for 4 weeks to evaluate toxicity. As a result of the test, no toxic symptoms due to the test substance were observed in any administration group, and the high dose of 10mg / kg / day was set as a non-toxic dose.
[0041] [Table 3]
[0042] Experimental Example 4: Confirmation of safety / PK / PD of single dose of fexprazan injection In order to confirm the safety / PK / PD of the compound of the present invention when administered intravenously, a clinical trial was designed to target healthy adults (Korean / Chinese) aged 19 to 50 years old, with random allocation, double-adventure, placebo control, single administration, and stepwise dose escalation.
[0043] The stabilizer (200 mg), the lyophilization auxiliary (200 mg), and the prepared fexprazan hydrochloride (40 mg by weight of fexprazan) were dissolved in water for injection (4 mL), and an appropriate amount of acid was added to adjust the pH to 4.0. The prepared solution was placed in a vial and dried by lyophilization to prepare a lyophilized agent.
[0044] Using the freeze-dried composition prepared as above, 28 test subjects were enrolled in 4 dose groups (10 mg, 20 mg, 40 mg, 80 mg) based on weight of fexprazan, 4 subjects, 8 subjects, 8 subjects, 8 subjects, respectively, and randomly assigned to the test group or control group in a 3:1 ratio in the order of passing the screening criteria. All test subjects completed safety, pharmacokinetic, and pharmacodynamic evaluations according to the planned clinical trial schedule.
[0045] [Table 4]
[0046] As shown in Figure 1, the screening visit was scheduled 3 to 28 days before the start of the clinical trial, and the patient was admitted to the hospital 2 days before dosing. The patient was administered the medication on the morning of the day, and was discharged on the 3rd day of dosing. The final visit was scheduled between 8 and 11 days after dosing.
[0047] Gastrointestinal acidity (pH) and gastrin, a hormone that promotes gastric secretion, were measured from 24 hours before to 24 hours after administration, and pharmacokinetic blood and urine samples were collected for 48 hours after administration. The pharmacokinetic parameters measured are shown in Tables 5 to 8 and Figures 2 to 5 below, and no significant abnormal symptoms or side effects were observed.
[0048] [Table 5]
[0049] [Table 6]
[0050] As shown in Table 6 and Figure 5, the results of checking the acidity (pH) in the gastrointestinal tract confirmed that after intravenous administration of 80 mg, the time during which the pH remained above 6 for 24 hours was 59.65%, and after intravenous administration of 40 mg, the time during which the pH remained above 6 for 12 hours was 50% or more. Therefore, it can be confirmed that the drug is effective in treating bleeding when administered once a day at 80 mg or more, and when administered twice a day at 40 mg or more.
[0051] Similarly, as shown in Table 6 and Figure 5, the results of confirming the acidity (pH) in the gastrointestinal tract confirmed that after intravenous administration of 20 mg, the time during which the pH remained at 4 or higher for 24 hours was 46.7%. This confirms that administration of 20 mg once a day is effective in treating diseases related to gastric acid secretion.
[0052] [Table 7]
[0053] After single intravenous administration of fexprazan in four dose groups, the dose proportionality of Cmax, AUClast, and AUCinf parameters of fexprazan was evaluated between 10 mg and 80 mg doses. The log-transformed parameters and the regression lines with 95% confidence intervals for each dose after single administration are shown in Table 7 and Figure 3, respectively. When single intravenous administration from 10 mg to 80 mg was evaluated using the power model, the slopes (95% confidence intervals) of the regression lines for Cmax, AUClast, and AUCinf were 0.89 (0.7477-1.0339), 1.10 (0.9884-1.2090), and 1.11 (0.9940-1.2182), respectively, showing a dose-proportional increase. In other words, it can be confirmed that the pK parameters of intravenous administration are proportional to the dose.
[0054] [Table 8]
[0055] Table 8 and Figure 4 show the results of the Kruskal Wallis test for dose-normalized Cmax (Cmax / Dose), AUClast (AUClast / Dose), and AUCinf (AUCinf / Dose). No statistical significance was observed for any of them (p=0.4045, 0.3430, 0.2961). In other words, there was no significant difference between dose groups in the proportional relationship, and it can be seen that the appropriate dose for intravenous administration can be indirectly calculated from the appropriate dose for oral administration.
[0056] As a result, clinical trials were conducted to confirm the bioavailability of the oral formulation, which is necessary for calculating the intravenous dose versus the oral dose.
[0057] Experimental Example 5: Confirmation of bioavailability (BA) of Fexprazan injection The dosage regimen for an injectable formulation can be determined by determining pharmacokinetic parameters such as the bioavailability and maximum blood concentration for oral administration compared to intravenous administration, and the resulting pharmacological parameters, and applying these to the dosage regimen for oral administration, to determine an appropriate dosage regimen for an injectable formulation.
[0058] Therefore, in order to compare the safety / PK / PD of the compound of the present invention when administered intravenously in a single dose and when administered orally in a single dose, and to derive the bioavailability, a randomized, open, single-dose, two-group, two-period crossover study was designed for healthy adults. The inclusion / exclusion criteria were the same as in Experimental Example 4. A total of eight test subjects were enrolled, and four subjects were randomly assigned to sequence group 1 or sequence group 2 in the order that they passed the screening criteria. All test subjects completed safety, pharmacokinetic and pharmacodynamic evaluations according to the planned clinical trial schedule.
[0059] [Table 9]
[0060] The subjects were scheduled to visit for screening 3 to 28 days before the start of the clinical trial and to be hospitalized 2 days before dosing. For the first dosing, the subjects were randomly assigned to the group on the morning of the day, and a composition was intravenously administered by dissolving a stabilizer (200 mg), a lyophilization aid (200 mg), and the prepared fexprazan hydrochloride (40 mg by weight of fexprazan) in water for injection (4 mL) and adjusting the pH to 4.0 by adding an appropriate amount of acid, or by mixing an excipient (100 mg), a disintegrant (5 mg), and the prepared fexprazan hydrochloride (40 mg by weight of fexprazan) and compressing them to prepare a tablet, which was then orally administered, and the subjects were discharged on the third day of dosing. For the second dosing, the subjects were hospitalized on the sixth day after the first dosing, progressed on the morning of the eighth day, and were discharged on the tenth day of dosing. The subjects were then scheduled to visit the hospital for the final visit between the 15th and 18th days of dosing (Figure 6).
[0061] Gastrointestinal acidity (pH) and gastric juice secretion promoting hormone gastrin tests were performed from 24 hours before to 24 hours after dosing in each period, and pharmacokinetic blood and urine samples were collected for 48 hours after dosing in each period. The pharmacokinetic parameters measured are shown in Tables 10 and 11 and Figure 7 below, and no significant abnormal signs or side effects were observed.
[0062] [Table 10]
[0063] [Table 11]
[0064] As can be seen from Table 10, the Cmax values for oral and intravenous administration of 40 mg of fexprazan were 49.9 μg / L and 277 μg / L, respectively, and the Tmax values were 2.09 h and 0.25 h, respectively. This indicates that the injection reached a higher maximum blood concentration (Cmax) at an earlier time than the oral administration. The AUClast values were 536 μg h / L and 1110 μg h / L, respectively, confirming that the bioavailability when administered orally was approximately 0.46.
[0065] The PD parameters are shown in Table 11. As a result of checking the acidity (pH) in the gastrointestinal tract, the ratio of time that the pH remained above 4 was confirmed to be 47.5% and 71.6% for oral and intravenous administration, respectively, and the ratio of time that the pH remained above 6 was confirmed to be 20.3% and 38.7% for oral and intravenous administration, respectively. In addition, the mean pH value was 3.9 and 4.9 for oral and intravenous administration, respectively.
[0066] Taking the results of Tables 10 and 11 and FIG. 7 together, it can be seen that the pharmacological effect (PD) of fexprazan is related to the blood concentration (PK) of fexprazan, and that intravenous administration has a faster Tmax, higher Cmax, and higher AUC value than oral administration, thereby providing a faster and higher pharmacological effect.
[0067] When the bioavailability confirmed above is substituted, it can be confirmed that intravenous administration of fexprazan at a dose 0.46 times that of oral administration shows the same pK data. Therefore, it can be inferred that oral administration of 40 mg of fexprazan and intravenous administration of 18.4 mg, which is 0.46 times that dose, have equivalent therapeutic effects.
[0068] Experimental Example 6: Confirmation of changes in PD values by multiple administration of fexprazan injection Following the above Experimental Example 4, in order to confirm the change in PD value when the compound of the present invention is administered multiple times, a randomized, double-blind, placebo-controlled clinical trial was designed for healthy adults aged 19 to 50 years.
[0069] The stabilizer (200 mg), the lyophilization auxiliary (200 mg), and the prepared fexprazan hydrochloride (40 mg by weight of fexprazan) were dissolved in water for injection (4 mL), and an appropriate amount of acid was added to adjust the pH to 4.0. The prepared solution was placed in a vial and dried by lyophilization to prepare a lyophilized agent.
[0070] Using the freeze-dried composition prepared as described above, a total of 25 test subjects were enrolled in three dose groups (20 mg, 40 mg, and 80 mg) based on the weight of fexprazan, with 9 subjects, 8 subjects, and 8 subjects in each group. They were randomly assigned to the test group or the control group in a 3:1 ratio per group based on the order of passing the screening criteria.
[0071] [Table 12]
[0072] Dose groups 1 and 3 in Table 12 above were administered once daily (every 24 hours) (Figure 8), and dose group 2 was administered twice daily (every 12 hours) for 7 days (Figure 9).
[0073] The gastrointestinal acidity (pH) test was performed for 48 hours from the day before administration until 24 hours after the first administration, and then for 24 hours after administration on the 7th day. The measurement results are shown in Table 13 and Figures 10 to 14 below.
[0074] [Table 13]
[0075] As can be seen from the above results, when 20 mg was administered once daily, the time during which the gastrointestinal pH remained above 4 on the 7th day was 55.68 (± 14.85)%, and when 40 mg was administered twice daily and 80 mg was administered once daily, the time during which the gastrointestinal pH remained above 6 on the 7th day was 74.77 (± 13.39)% and 70.07 (± 18.09)%, respectively.
[0076] Experimental Example 7: Confirmation of changes in PD values following maintenance therapy with fexprazan injection To confirm the change in PD value due to maintenance therapy with fexprazan injection, a study was conducted on eight healthy adults between the ages of 19 and 50. The subjects were administered 100ml of a solution of 40mg of lyophilized formulation (40mg / vial) and saline, which was manufactured in the same manner as in Experimental Example 6, intravenously for 30 minutes. Thereafter, on the first day, a total of 1L of a solution of 94mg of lyophilized formulation (40mg / vial) and saline was administered intravenously for 23.5 hours, and on the second and third days, a total of 1L of a solution of 96mg of lyophilized formulation (40mg / vial) and saline was administered intravenously for 24 hours each. In other words, a total of 3L of a solution of 286mg of lyophilized formulation (40mg / vial) and saline was administered intravenously for 71.5 hours at a rate of 4mg / hr. The gastrointestinal acidity test was performed on the first and third days, and the results are shown in Table 14 below and FIG.
[0077] [Table 14]
[0078] As can be seen from the above results, after intravenous administration of 40 mg, when maintained at 4 mg / h for 71.5 hours, the time during which the pH in the gastrointestinal tract remained above 6 was 76.33 (±15.98)%, which suggests that this therapy is effective in preventing bleeding.
Claims
1. An injectable composition for preventing or treating a gastrointestinal disease, comprising a compound represented by the following formula 1 or a pharma- ceutical acceptable salt thereof, administered at a dose 0.4-0.6 times the dose at which a therapeutic effect has been confirmed for oral administration: <Chemical formula 1>
2. An injectable composition for preventing or treating a gastrointestinal disease, comprising a compound represented by the following formula 1 or a pharma- ceutical acceptable salt thereof, administered in an amount of 10 mg to 30 mg once a day: <Chemical formula 1>
3. The gastrointestinal disease is a disease associated with gastric acid secretion. The injectable composition according to claim 1 or 2.
4. The gastrointestinal disease is reflux esophagitis. The injectable composition according to claim 1 or 2.
5. The gastrointestinal disease is erosive esophagitis. The injectable composition according to claim 1 or 2.
6. An injection composition for treating bleeding, comprising a compound represented by the following chemical formula 1 or a pharma- ceutical acceptable salt thereof, administered once a day in an amount of 70 mg to 90 mg, or twice a day in an amount of 30 mg to 50 mg: <Chemical formula 1>
7. The bleeding is due to a digestive ulcer. The injectable composition according to claim 6.
8. The bleeding is due to iatrogenic ulcer after endoscopic procedure; The injectable composition according to claim 6.
9. An injection composition for preventing bleeding, comprising administering a compound represented by the following formula 1 or a pharma- ceutical acceptable salt thereof at a dose of 30 mg to 50 mg, followed by administration at a rate of 1 mg / h to 10 mg / h for 24 hours or more: <Chemical formula 1>
Citation Information
Patent Citations
Novel application of gastric acid secretion inhibitor
CN106511344A
Liquid formulations of amines and organic acids stabilized by salts
JP2015521986A
Novel 4-methoxypyrrole derivative or its salt and pharmaceutical composition containing the same
JP2017538716A
Spiral duct capable of preventing flow of fluid and manufacture method therefor
KR1020220168665A
